1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
Complex Regional Pain Syndrome (CRPS) - Epidemiology Forecast to 2030

Complex Regional Pain Syndrome (CRPS) - Epidemiology Forecast to 2030

  • January 2021
  • 80 pages
  • ID: 6010476
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Complex Regional Pain Syndrome (CRPS) - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted CRPS epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Complex Regional Pain Syndrome (CRPS) Understanding
Complex regional pain syndrome (CRPS) is one of the most challenging chronic pain condition that is characterized by progressively worsening spontaneous regional pain without dermatomal distribution. The pain experienced is out of proportion in time and severity to the inciting event and accompanied by symptoms that vary in severity including skin changes, autonomic dysfunction, abnormal sensory and motor changes, and trophic changes. CRPS may develop after major trauma, surgery, or minor injury, and progresses with a variable course that ranges from self-limiting, mild symptomatology to chronic disease. In many cases, disease progression is debilitating and severely limits patients’ quality of life, creating a tremendous burden on patients and their families. Over time, CRPS has been defined and redefined. CRPS develops after an inciting noxious stimulus to an affected limb. There is little agreement with regards to the etiology, symptoms, clinical presentation, diagnosis, or treatment of CRPS.
In order to bring some uniformity to this problem, the International Association for the Study of Pain (IASP) in 1994 introduced the term CRPS to describe a wide variety of post-traumatic neuropathic pain conditions of the limbs. There are two types of CRPS, Type I occurs after an illness or injury that did not directly damage a nerve in the affected area, and Type II follows a distinct nerve injury. Although the triggers vary, both types of CRPS have the same symptoms and go through the same three stages of the disease. CRPS used to be known as reflex sympathetic dystrophy (RSD) (Type I) and causalgia (Type II). Type I comprises about 90 percent of all cases of CRPS. Patients typically progress through three stages —Stage I or acute stage (may last up to 3 months), Stage II or Dystrophic stage (can last 3–12 months), Stage III and atrophic stage (occurs after 1 year). There are no objective diagnostic tests for CRPS. Since, its pathophysiologic basis of CRPS is not fully understood, mechanism-based diagnosis is not yet feasible. Therefore, the diagnosis of CRPS is based solely on clinical signs and symptoms. The actual diagnosis of CRPS is made solely based on history and physical examination to determine whether a patient meets CRPS diagnostic criteria (often called the Budapest criteria). Other than this, objective testing (thermography, triple-phase bone scan, quantitative sudomotor axon reflex test, or a trial sympathetic ganglion block) may be used to support a clinical diagnosis.

Epidemiology Perspective
The CRPS epidemiology division provides the insights about historical and current CRPS patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
In the year 2017, the total prevalent case of CRPS was 310,489 cases in the 7MM which are expected to grow during the study period, i.e., 2017–2030.
The disease epidemiology covered in the report provides historical as well as forecasted CRPS epidemiology [segmented as Total prevalent cases of CRPS, Total diagnosed prevalent cases of CRPS, Gender-specific diagnosed prevalent cases of CRPS, Age-specific diagnosed prevalent cases of CRPS, Type-specific diagnosed prevalent cases of CRPS, Severity-specific diagnosed prevalent cases of CRPS, and Total Treated Cases of CRPS scenario of CRPS in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.

Country Wise- CRPS Epidemiology
• In the United States, the total number of prevalent cases of CRPS was 219,317 cases in the year 2017 which are expected to grow during the study period, i.e., 2017–2030.
• In the year 2017, the total prevalent cases of CRPS were 84,850 cases in EU-5 which are expected to grow during the study period, i.e., 2017–2030.
• In Japan, the total number of prevalent cases of CRPS was 6,323 cases in the year 2017 which are expected to grow during the study period, i.e., 2017–2030.
• In the 7MM, the total gender-specific diagnosed prevalent cases of CRPS were 47,699 for males and 102,987 for females in the year 2017.
• In 7MM, the highest number (~87% of CRPS cases) of type-specific diagnosed prevalent cases recorded in 2017 for CRPS I, i.e., 131,278 cases.
• This condition affects people of all ages. Around 3/4th cases of CRPS are reported in the people age group of 20–60 years of age. In the 7MM, the age-specific diagnosed prevalent cases for age-group 40–59 years were 72,247 in 2017.

Scope of the Report
• The CRPS report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• The CRPS Report and Model provide an overview of the risk factors and global trends of CRPS in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
• The report provides insight about the historical and forecasted patient pool of CRPS in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of CRPS.
• The report provides the segmentation of the CRPS epidemiology by prevalent cases in the 7MM.
• The report provides the segmentation of the CRPS epidemiology by total diagnosed prevalent cases in the 7MM.
• The report provides the segmentation of the CRPS epidemiology by gender-specific diagnosed prevalent cases in the 7MM.
• The report provides the segmentation of the CRPS epidemiology by age-specific diagnosed prevalent cases in the 7MM.
• The report provides the segmentation of the CRPS epidemiology by type-specific diagnosed prevalent cases in the 7MM.
• The report provides the segmentation of the CRPS epidemiology by severity-specific cases of CRPS in the 7MM.
• The report provides the segmentation of the CRPS epidemiology by treated cases of CRPS in the 7MM.

Report Highlights

• 11-Year Forecast of CRPS epidemiology
• 7MM Coverage
• Total prevalent Cases of CRPS
• Total diagnosed prevalent cases of CRPS
• Gender-specific diagnosed prevalent cases of CRPS
• Age-specific diagnosed prevalent cases of CRPS
• Type-specific diagnosed prevalent cases of CRPS
• Severity-specific diagnosed prevalent cases of CRPS
• Treated cases of CRPS
KOL-Views
We interview, KOL’s and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over CRPS scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to CRPS?
• What are the key findings pertaining to the CRPS epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017–2030)?
• What would be the total number of patients of CRPS across the 7MM during the study period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2017–2030)?
• At what CAGR the patient population is expected to grow in the 7MM during the study period (2017–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of CRPS?

Reasons to buy
The CRPS Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global CRPS market
• Quantify patient populations in the global CRPS market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for CRPS therapeutics in each of the markets covered
• Understand the magnitude of CRPS population by its severity
• The CRPS epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The CRPS Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Granulomatosis with Polyangiitis - Epidemiology Forecast to 2030

  • $ 3750
  • April 2021
  • 60 pages

‘Granulomatosis with polyangiitis (GPA) – Epidemiology Forecast – 2030’ report delivers an in-depth understanding of the historical and forecasted epidemiology of GPA in the United States, EU5 ...

  • Germany
  • United States
  • Epidemiology
  • Industry analysis

ref:plp2020

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on